| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | FCRL3; FCRH3; IFGP3; IRTA3; SPAP2 |
| Entrez GeneID | 115352 |
| clone | 4B4B2 |
| WB Predicted band size | 80.9kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD307C (AA: extra 18-153) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD307c(FCRL3)抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**：*FCRL3 inhibits TLR-activated B cell activation by suppressing NF-κB signaling*
**作者**：Li FJ, et al.
**摘要**：该研究探讨CD307c(FCRL3)在B细胞中的调控作用，发现其通过抑制NF-κB信号通路负向调控Toll样受体(TLR)介导的B细胞活化，提示其在自身免疫病中的潜在治疗价值。
---
2. **文献名称**：*FCRL3 polymorphisms as risk factors for autoimmune thyroid disease*
**作者**：Simmonds MJ, et al.
**摘要**：通过基因关联分析，发现FCRL3(CD307c)基因多态性与自身免疫性甲状腺疾病(如Graves病)的易感性相关，表明其抗体可能作为疾病生物标志物或干预靶点。
---
3. **文献名称**：*FCRL3 regulates B cell receptor signaling and immune complex internalization*
**作者**：Wilson TJ, et al.
**摘要**：研究揭示了CD307c抗体在B细胞受体(BCR)信号转导中的作用，证明其通过调控免疫复合物内吞过程影响B细胞功能，可能参与肿瘤微环境的免疫逃逸机制。
---
注：CD307c(FCRL3)相关研究多集中于其基因多态性与自身免疫疾病或肿瘤的关联，直接针对其抗体的功能研究较少，以上文献均涉及该分子在免疫调控中的机制。如需具体文献链接或补充，可提供更详细需求。
The CD307c antibody targets the CD307c protein, a member of the Fc receptor-like (FCRL) family, which is predominantly expressed on B lymphocytes. Discovered in the early 2000s, FCRL proteins share structural homology with classical Fc receptors but lack direct binding to immunoglobulins. CD307c, encoded by the *FCRL3* gene, contains immunoreceptor tyrosine-based activation and inhibition motifs (ITAM/ITIM), suggesting dual roles in modulating B-cell signaling. It is implicated in regulating immune activation and tolerance, with studies linking its dysregulation to autoimmune diseases like rheumatoid arthritis and lupus.
CD307c antibodies are valuable tools for investigating B-cell biology, particularly in understanding how FCRL proteins fine-tune antigen receptor signaling. They enable detection of CD307c expression via flow cytometry, immunohistochemistry, or Western blotting, aiding research into its tissue-specific distribution and functional relevance. Aberrant CD307c expression has been observed in B-cell malignancies, positioning it as a potential diagnostic or therapeutic target. Recent efforts explore its utility in monoclonal antibody-based therapies or as a biomarker for disease progression. However, its precise ligand interactions and signaling mechanisms remain under active investigation, highlighting the need for further studies to unlock its clinical potential in immunology and oncology.
×
